Skip to content
2000
Volume 12, Issue 21
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Schizophrenia has been historically characterized by the presence of positive symptomatology, however, decades of research highlight the importance of cognitive deficits in this disorder. At present, cognitive impairments remain one of the most important unmet therapeutic needs in schizophrenia. The prefrontal cortex (PFC) controls a large number of higher brain functions altered in a variety of psychiatric disorders, including schizophrenia. Histological studies indicate the presence of a large proportion of PFC neurons expressing monoaminergic receptors sensitive to the action of current atypical antipsychotics. Functional studies also show that these medications act at PFC level to increase dopamine neurotransmission in the mesocortical pathway. Here we focus on monoaminergic molecular targets that are actively being explored as potential therapeutic agents in the basic and clinical cognitive neuroscience research, to support the development of co-treatments used in conjunction with antipsychotic medications. These targets include dopamine and serotonin receptors in the prefrontal cortex, as well as elements of the noradrenergic system.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/156802612805289872
2012-11-01
2025-06-01
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/156802612805289872
Loading

  • Article Type:
    Research Article
Keyword(s): Antipsychotic drugs; cognitive deficits; monoamines; prefrontal cortex; schizophrenia
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test